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Introduction
Systemic  Lupus  Erythematosus  (SLE)  is  a  multisystemic
autoimmune  disease  of  unknown  origin  with  a waxing  and
waning  course  and  a  significant  morbi-mortality.  The  objec-
tive  of  this  paper  is  to  provide  an  SLE  overview,  as  well
as  recommendations  regarding  diagnosis  and  therapeutic
concepts.  In  the  first  stage  of  the disease,  the  combina-
tion  of  genetic,  gender  and  environmental  factors  culminate
in  the  formation  of  autoantibodies  years  before  the  onset
of  symptoms  is  observed.  In  the second  phase,  there  are
clinical  manifestations  and  associations  with  comorbidities.
Management  of  patients  with  SLE  should  be  predictive,  pre-
ventive,  personalized,  and participatory  in order  to  achieve
remission  and  prevent  relapses.  We  can  divide  SLE  into
three  categories  according  to  the severity  of  the disease:
mild,  moderate,  and severe.  Corticosteroids  are the  main-
stay  of  therapy,  but  the use  of  another  agent  is  mandatory  in
order  to reduce  side  effects.  Some  of  the biological  agents
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used  in immunosuppressive  therapy in  SLE treatment  include
methotrexate,  antimalarials,  azathioprine,  mycophenolate
mofetil,  cyclophosphamide,  belimumab  and  rituximab.
Background
Diagnosing  Systemic  Lupus Erythematosus  (SLE)  has  been  a
challenge  over the years.  The  first  reports  of  the  disease
only considered  skin  manifestations.  Later,  William  Osler
recognized  the  systemic  involvement  of  the disease.1 SLE
is  a multisystemic  autoimmune  disease  of  unknown  origin.2
SLE  has  an  incidence  of  1--10 per  100,000  person-years  and
a  prevalence  of  20--70  per  100,000  inhabitants.3 SLE  preva-
lence  in Hispanics  is  138.7--244.5  per  100,000  people.4 For
every  9--10 women  with  SLE,  1  male  will  be affected.2 SLE
has  a waxing  and  waning  course  with  significant  morbidity
that  can be  fatal  --  if not  treated  early  --  in some  patients.
A  diagnosis  of  SLE  should  be considered  when a patient  has
characteristic  features  of  SLE  associated  with  autoantibody
formation5;  thus, the  presence  of  anti-nuclear  antibodies
(ANA)  is  considered  necessary  for  an SLE  diagnosis.  Patients
without  ANA  will  have  less  than  a  3% probability  of  develop-
ing  the  disease.
The  objectives  of  this paper  are to  provide  an  overview
based  on the literature  and on  the personal  experience  of
30  years  of treating  patients  with  SLE,  provide  general  and
specific recommendations  regarding  the diagnosis  of this
challenging  disease,  and  share  therapeutic  concepts  that
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Figure  1  Proposed  current  stages  for  developing  clinical  man-
ifestations  of  Systemic  Lupus  Erythematosus.
are  fundamental  for  the  comprehensive  management  of  the
disease.
SLE  stages
SLE  stages  include  a preclinical  and  a clinical  phase,  as  well
as  its  related  comorbidities.
Clinical  manifestations  only  develop  in predisposed  indi-
viduals  and  are  secondary  to  a  loss  of  tolerance  with  a
subsequent  immune  dysregulation6 (Fig.  1). The  develop-
ment  of  autoimmunity  is  determined  by  genetic,  gender,
and  environmental  factors.  Advances  in genetic  techniques
have  identified  more  than  30  genetic  associations  with  SLE
including  variants  of  HLA  and  Fc receptor  genes,  IRF5,
STAT4,  PTPN22,  TNFAIP3,  BLK,  BANK1,  TNFSF4  and  ITGAM.7
Moreover,  the  genetic  contribution  to  the development
of  SLE  has been observed  in twins,  with  a concordance
between  monozygotic  twins  of  24--56%  vs  2--5%  in dizy-
gotic  twins.8 Female  preponderance  in the  pathogenesis
of  SLE  has  been  demonstrated  in  transgenic  mice.  Smith-
Bouvier  et  al.  observed  that  mice  with  the  XX  chromosome
were  more  susceptible  to  developing  lupus  when  compared
to  XY  mice.9 Environmental  factors  can  contribute  to  the
development  of SLE  by the inhibition  of DNA  methylation.10
These  factors  include  drugs  (e.g.  procainamide),  diet,  smok-
ing,  UV  light  exposure  and  infections  (Epstein--Barr  virus).11
Finally,  there  is  a pathogenic  autoantibody  production  in SLE
patients,  reflecting  loss  of  tolerance.6
Different  authors  have  described  the development  of
autoantibodies  before  the clinical  onset  of  the disease
in  the  past.  Arbuckle  et al.  described  the presence  of
at  least  one  SLE  autoantibody  before  the diagnosis  (up
to  9.4  years  earlier;  mean,  3.3  years)  in asymptomatic
patients.  Antinuclear,  antiphospholipid,  anti-Ro  and  anti-La
antibodies  preceded  the  other  autoantibodies  in this  cohort
of  patients.12 Subsequently,  McClain  et al.  described  the
clinical  significance  of  the presence  of  antiphospholipid  anti-
bodies  prior  to  an SLE  diagnosis,  as  well  as  the  presence  of
these  autoantibodies  in patients  with  a  more  severe  clinical
outcome.13
In order  to  classify  patients  in  the  early  stages  of the dis-
ease,  different  authors  have  proposed  definitions  according
Table  1  General  recommendations  for  SLE* patients.
Balanced  diet  and  exercise
Avoid substances  and  drugs  that  might  induce  lupus
No smoking
Vaccination  schedule
Assessment  of  cardiovascular  risk factors
Screening  of  cancer
Evaluation  of  reproductive  health
Assessment  of  cognitive  function
* Systemic lupus erythematosus.
to  the symptoms  and  the  presence  of  classification  criteria.
First,  the  term  undifferentiated  connective  tissue  disease
(UCTD)  is  used  in individuals  with  a disease  manifestation
suggestive  but  not  diagnostic  of  a  specific  connective  tis-
sue  disease.  UCTD accounts  for  10--20% of referred  patients,
10--15%  will  fulfill  the classification  criteria  for  SLE  5 years
later.14 Factors  that predict  evolution  to  SLE  are  young
age,  alopecia,  serositis,  discoid  lupus,  a  positive  anti-human
globulin  (Coombs)  test  and  anti-Sm  or  anti-DNA  antibodies.15
Ganczarczyk  et al. described  the term  ‘‘latent  lupus’’  to
define  patients  with  features  consistent  with  SLE which may
or  may  not  be a  part of  the  American  College  of Rheumato-
logy  (ACR)  classification  criteria,  but  still  are  ≤4.16
Incomplete  lupus refers  to  patients  with  less  than  four
ACR  classification  criteria  for  SLE.  Swaak  et  al. in a  multicen-
tric  study, observed  that  only  three  of 122  incomplete  lupus
patients  developed  SLE  during 3  years  of  follow-up,  and  sug-
gested  that  incomplete  SLE  forms  a  subgroup  with  a good
prognosis.17 Later,  Greer  et al.  confirmed  this observation.
They  followed  38  incomplete  lupus patients  over  19  months
and  only two  developed  SLE.18 An  additional  term  is  preclin-
ical  lupus,  which defines  individuals  with  increased  genetic
risk  for  the  development  of  SLE  but  no  clinical  symptoms.19
After  the preclinical  stage,  the clinical  stage  occurs  with
the  onset  of  symptoms.  The  GLADEL  (Grupo  Latinoameri-
cano  de Estudio  de  Lupus)  cohort,  a  multinational  inception
prospective  cohort  in  Latin  American  centers,  described  the
symptoms  in 1214  patients  with  SLE.  They  found that  arthral-
gia  and/or  arthritis,  fever,  photosensitivity,  alopecia  and
malar  rash were  the most  common  symptoms  at  onset.20
SLE  treatment
SLE management  represents  the  ‘‘P4’’,  a  new  paradigm  of
modern  medicine.  P4  Medicine  stands  for  Predictive,  Pre-
ventive,  Personalized  and Participatory  Medicine.
SLE  is  a  syndrome  with  high  variability  in the  disease
course  as  well  as in  the severity  of the  manifestations;
therefore  each SLE  patient  should be  treated  on an  individ-
ualized  basis  in order  to  implement  a proper  treatment.21
The  goal  of  the treatment  is  to  achieve  remission,  prevent
flares  and  use  of drugs  with  the  minimum  dose  required
to  prevent  long-term  side  effects.  The  treatment  includes
lifestyle  modification,  patient  education,  physical  activity
and  medical  or  (in  some cases)  surgical  intervention.
There  are general  recommendations  that  are given  to
SLE  patients  (Table  1). All  patients  should  have  a bal-
anced  diet  and exercise  regularly.  Patients  are advised  to
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avoid  Echinacea,  melatonin,  garlic,  and  alfalfa  sprouts,
which  have  been  described  to  precipitate  their  condition.22
It  is  also  important  to  inform  patients  to  avoid  disease
reactivation  drugs  such  as  procainamide,  hydralazine,  sul-
fonamides,  anti-TNFa,  ibuprofen  or  estrogen.23,24 Smoking
also  appears  to  influence  the onset  and  course  of  the  dis-
ease  among  patients  with  SLE.25,26 The  effect  of  drugs
like  methotrexate  (MTX)  and hydroxychloroquine  (HCQ)  may
diminish  with  smoking.
The  vaccination  schedule  in SLE  patients  includes  a yearly
influenza  vaccine  and a pneumococcal  vaccine  every  5 years.
Hepatitis  B  and  Tetanus  toxoid  vaccinations  also  seem  to
be  safe,  and  not  associated  with  flares.27 The  quadrivalent
human  papillomavirus  vaccine  is  also  safe  and  not  asso-
ciated  with  increased  lupus  activity.28 It is  important  to
consider  that  inactivated  live  vaccines  are  contraindicated
in  patients  taking  immunosuppressive  drugs  and/or  gluco-
corticoids  at  a  dose >20  mg/day.27
Most  SLE  patients  are diagnosed  in the reproductive
years,  thus  reproductive  health  is an important  issue.  It is
recommended  for  SLE  patients  to have  an inactive  disease
for  a  six  month  period  prior  to  conception.  There  are three
main  types  of  contraceptives:  barrier  methods,  intrauter-
ine  devices  and the  hormonal  method.  Hormonal  methods
include  combined  or  progestin-only.  The  use  of combined
methods  is associated  with  an  increased  risk  of SLE,29 how-
ever,  progesterone  methods  have proven  to  be  safe for  SLE
patients.30
In  addition  to the control  of the disease,  SLE  patients
should  have  a systematic  assessment  of  comorbidities.  SLE
patients  develop  premature  atherosclerosis  and  their  risk
of  heart  attack  and  stroke  is  10  times  higher  than  that
of  age-matched  controls.31 Atherosclerosis  is  the result
of  the  complex  interplay  between  dysfunctional  immune
regulation,  inflammation,  traditional  risk  factors,  aberrant
endothelial  cell function  and repair,  and  the  therapeutics  for
treating  the  underlying  autoimmune  disease.32 SLE  patients
also  have  an  increased  risk  of different  types  of  cancer  such
as  non-Hodgkin  lymphoma,  lung  cancer,  and  cervical  dyspla-
sia.  Lupus  disease  activity,  smoking  and  immunosuppressive
drug  exposure  are some  of  the causes  of the increase  in
cancer  risk.33 Therefore,  SLE  patients  should  have colonos-
copies,  Pap  smear, and  mammogram  schedules.
Cognitive  dysfunction  prevalence  in SLE  ranges  from
12%  to  87%.  Petri  et  al. compared  cognitive  functioning
in  recently  diagnosed  SLE  patients  versus  normal  controls.
Using  Automated  Neuropsychological  Assessment  Metrics
(ANAM),  SLE  patients  performed  significantly  worse  than
normal  controls.  Therefore,  a  cognitive  assessment  is  nec-
essary  in  all  SLE  patients  from  the  onset  of  the disease.
We  can  divide  SLE  into  three  categories  based  on disease
severity:  mild,  moderate,  and  severe  (Fig.  2).
Corticosteroids  (CS)  are the mainstay  of treatment
for  SLE  in  any  category,  with  proven  efficacy.34 The
dose  varies  according  to  the severity  of symptoms.  A
low  dose  is  0.1--0.2 mg/kg/day,  an intermediate  dose  is
0.3--0.5  mg/kg/day,  and  a  high  dose  is  0.6--2  mg/kg/day.  The
use  of  this  drug  is  associated  with  an increase  in serum  lipids,
blood  pressure,  weight  and  glucose,  in addition  to  cataracts
and  osteoporotic  fractures.  The  adverse  side  effects  of CS
depend  on  both  the current  and the  cumulative  dosage.
Thamer  et  al. demonstrated  the hazard  ratio  for  accrued
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Figure  2  Stepwise  approach  in the  treatment  of  SLE.
NSAID, Nonsteroidal  antiinflammatory  drugs;  IVIg, intravenous
immunoglobulin;  SLE,  systemic  lupus  erythematosus.
organ damage  to  be 1.5,  1.64  and 2.51  with  prednisone  doses
of  6  mg/day,  12  mg/day  and  >18  mg/day,  respectively.35 It
is important  to  note  that  SLE  diagnosis  is  not equivalent
to  the use  of  methylprednisolone,  and  that in many  cases
the  deleterious  effects  of CS  may  outweigh  the benefits.
Therefore,  the  goal  is  the  use  of CS  according  to  the  clinical
manifestations  and slow  tapering  to  1--2  mg/day.  In order  to
reduce  CS  doses  and  side  effects,  the use  of  another  agent
is  mandatory.34
Mild SLE  includes  mucocutaneous  lesions,  arthralgias  and
fatigue.  Sun  protection  consists  of  avoiding  when the  sun
is  at its  highest  (10 am  to  4  pm)  and  patients  should  use
agents  with  a sun  protection  factor  of  at least  50, applied
20--30  min prior  to  exposure,  and  reapplied  every  4  h. Topical
therapies  depend  on  whether  it is  a localized  or  widespread
skin  disease.  Therapies  include  steroids  and/or  calcineurin
inhibitors.36 Systemic  therapies  include  antimalarial  agents,
MTX,  azathioprine,  mycophenolate  mofetil  (MMF),  dapsone,
and cyclophosphamide  (CYC),  and  are  used in refrac-
tory  diseases  or  in poor  responses  to  treatment.34,36 For
cutaneovascular  manifestations  (Raynaud  syndrome,  livedo
reticularis,  etc.) the  use  of  cold-preventive  measures  and
calcium  channel  blockers  can  be beneficial.  Nonsteroidal
antiinflammatory  drugs (NSAID)  can be  used  in headaches,
myalgias,  arthralgias,  and serositis.  NSAID  use  must  be
monitored;  side  effects  could  be  renal,  gastrointestinal  or
cardiovascular.  In  my  experience,  I have  seen  severe  sec-
ondary  side  effects  such as  aseptic  meningitis.  Ibuprofen  is
the  drug most  frequently  involved  in aseptic  meningitis,  but
sulindac  and naproxen  have  also  been  described.37
Moderate  SLE  includes  arthritis,  serositis,  and  crops  of
mouth  ulcers.  Arthritis  can  improve  with  NSAID,  moder-
ate  doses  of  prednisone,  or  antimalarial  drugs.  When  the
response is  poor,  MTX,  leflunomide,  azathioprine  and  TNF-
a agents  can be used.38 Serositis  (pleurisy,  pericarditis)
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responds  to  NSAID  and  CS.  Belimumab  is  a  fully  human-
ized  IgG1  mAb  that binds  to  soluble  BLyS  (B  lymphocyte
stimulator),  inhibiting  its  activity.21 BLISS-52  and  BLISS  76
demonstrated  significant  clinical  responses  with  Belimumab
compared  to  placebos  in  patients  with  mild  and  moderate
disease  activity  (without  nephritis/CNS).39,40
The  severe  SLE  stage  includes  hemolytic  anemia,
thrombocytopenia,  diffuse  alveolar  hemorrhage,  necrotiz-
ing  vasculitis,  neuropsychiatric  lupus  and renal  involvement.
In  this  stage,  CS  is used  in high  doses  and  intravenous
methylprednisolone  pulses  for  severe  cases.  In hemolytic
anemia  and  thrombocytopenia  the  treatment  includes  CS
and  danazol,  Rituximab,  intravenous  immunoglobulin  (IVIg),
MMF,  CYC,  plasmapheresis  and/or  splenectomy  for  refrac-
tory  cases.41 The  use  of CYC  and high  doses  of  CS  are
also  employed  for  diffuse  alveolar  hemorrhage,  and  plasma-
pheresis  for refractory  cases.  We  made  an  observational,
retrospective  study  that  included  twelve  SLE  patients  with
alveolar  hemorrhage.  We  found  that  simultaneous  treat-
ment  with  CS,  CYC,  plasmapheresis  and IVIg  was  associated
with  a  mortality  of  17%, contrary  to  the rate  previously
described  of  up  to  70--90%.42
According  to  the  recommendations,  glucocorticoid  and
immunosuppressive  therapy  is  indicated  for  severe  neu-
ropsychiatric  manifestations  (myelopathy,  optic  neuritis,
etc.).  Anticoagulation  therapy  is indicated  for  the  SNC  man-
ifestations  of  antiphospholipid  syndrome.43 In  our  practice,
we  have  also observed  that  the  combination  of  methylpred-
nisolone,  CYC,  IVIg  and  Rituximab  was  effective  for  psychosis
refractory  to  conventional  treatment.
Renal  involvement  is  considered  the most important
prognostic  factor.  The  Task  Force  Panel  for  screening,
treatment,  and management  of  Lupus  Nephritis  (LN)  rec-
ommended  the treatment  to  be  based  on the  type of LN
according  to  the ISN/RPS  criteria.44 The  treatment  consists
of  the  use of  corticosteroids  either  solely  or  in  combina-
tion  with  immunosuppressive  agents.  The  recommendations
for  LN  treatment  include  an  induction  and  a maintaining
therapy.  There  are  2 regimens  for  Class  III/IV  LN,  low-
dose  ‘‘Euro-Lupus’’  CYC  and  high-dose  CYC  followed  by
maintenance  treatment  with  MMF  or  azathioprine.45 In our
practice,  we  believe  that a low-dose  CYC  is  more  beneficial
to  patients  decreasing  adverse  effects,  such as  infections,
gonadal  toxicity  and increased  risk  of  cancer.  We  do  not
share  the  idea  that methylprednisolone  pulses  will  provide
a  greater  benefit  than  prednisone.  And  finally,  LN  response
should  be  evaluated  3--6  months  after  initiating  treatment.
In conclusion,  SLE  is  a  challenging  disease  to  diagnose
and  treat.  Advances  in research  have  allowed  us to  know
which  individuals  are at risk  of  developing  the disease.  Each
patient  should  be  treated  on  an individualized  basis  accord-
ing  to  their clinical  manifestations  in order  to  provide  proper
treatment.
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